A computational toolbox and step-by-step tutorial for the analysis of neuronal population dynamics in calcium imaging data, bioRxiv, 2017-01-29

The development of new imaging and optogenetics techniques to study the dynamics of large neuronal circuits is generating datasets of unprecedented volume and complexity, demanding the development of appropriate analysis tools. We present a tutorial for the use of a comprehensive computational toolbox for the analysis of neuronal population activity imaging. It consists of tools for image pre-processing and segmentation, estimation of significant single-neuron single-trial signals, mapping event-related neuronal responses, detection of activity-correlated neuronal clusters, exploration of population dynamics, and analysis of clusters’ features against surrogate control datasets. They are integrated in a modular and versatile processing pipeline, adaptable to different needs. The clustering module is capable of detecting flexible, dynamically activated neuronal assemblies, consistent with the distributed population coding of the brain. We demonstrate the suitability of the toolbox for a variety of calcium imaging datasets, and provide a case study to explain its implementation.

biorxiv neuroscience 0-100-users 2017

A Fast Approximate Algorithm for Mapping Long Reads to Large Reference Databases, bioRxiv, 2017-01-28

AbstractEmerging single-molecule sequencing technologies from Pacific Biosciences and Oxford Nanopore have revived interest in long read mapping algorithms. Alignment-based seed-and-extend methods demonstrate good accuracy, but face limited scalability, while faster alignment-free methods typically trade decreased precision for efficiency. In this paper, we combine a fast approximate read mapping algorithm based on minimizers with a novel MinHash identity estimation technique to achieve both scalability and precision. In contrast to prior methods, we develop a mathematical framework that defines the types of mapping targets we uncover, establish probabilistic estimates of p-value and sensitivity, and demonstrate tolerance for alignment error rates up to 20%. With this framework, our algorithm automatically adapts to different minimum length and identity requirements and provides both positional and identity estimates for each mapping reported. For mapping human PacBio reads to the hg38 reference, our method is 290x faster than BWA-MEM with a lower memory footprint and recall rate of 96%. We further demonstrate the scalability of our method by mapping noisy PacBio reads (each ≥ 5 kbp in length) to the complete NCBI RefSeq database containing 838 Gbp of sequence and > 60, 000 genomes.

biorxiv bioinformatics 100-200-users 2017

A randomized placebo-controlled trial on the antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression, bioRxiv, 2017-01-28

AbstractRecent open label trials show that psychedelics, such as ayahuasca, hold promise as fast-onset antidepressants in treatment-resistant depression. In order to further test the antidepressant effects of ayahuasca, we conducted a parallel-arm, double-blind randomized placebo-controlled trial in 29 patients with treatment-resistant depression. Patients received a single dose of either ayahuasca or placebo. Changes in depression severity were assessed with the Montgomery–Åsberg Depression Rating Scale (MADRS) and the Hamilton Depression Rating scale (HAM-D). Assessments were made at baseline, and at one (D1), two (D2) and seven (D7) days after dosing. We observed significant antidepressant effects of ayahuasca when compared to placebo at all timepoints. MADRS scores were significantly lower in the ayahuasca group compared to placebo (at D1 and D2 p=0.04; and at D7 p<0.0001). Between-group effect sizes increased from D1 to D7 (D1 Cohen’ s d=0.84; D2 Cohen’ s d=0.84; D7 Cohen’ s d=1.49). Response rates were high for both groups at D1 and D2, and significantly higher in the ayahuasca group at D7 (64% vs. 27%; p=0.04), while remission rate was marginally significant at D7 (36% vs. 7%, p=0.054). To our knowledge, this is the first controlled trial to test a psychedelic substance in treatment-resistant depression. Overall, this study brings new evidence supporting the safety and therapeutic value of ayahuasca, dosed within an appropriate setting, to help treat depression.

biorxiv clinical-trials 0-100-users 2017

Nucleotide sequence and DNaseI sensitivity are predictive of 3D chromatin architecture, bioRxiv, 2017-01-28

AbstractRecently, Hi-C has been used to probe the 3D chromatin architecture of multiple organisms and cell types. The resulting collections of pairwise contacts across the genome have connected chromatin architecture to many cellular phenomena, including replication timing and gene regulation. However, high resolution (10 kb or finer) contact maps remain scarce due to the expense and time required for collection. A computational method for predicting pairwise contacts without the need to run a Hi-C experiment would be invaluable in understanding the role that 3D chromatin architecture plays in genome biology. We describe Rambutan, a deep convolutional neural network that predicts Hi-C contacts at 1 kb resolution using nucleotide sequence and DNaseI assay signal as inputs. Specifically, Rambutan identifies locus pairs that engage in high confidence contacts according to Fit-Hi-C, a previously described method for assigning statistical confidence estimates to Hi-C contacts. We first demonstrate Rambutan’s performance across chromosomes at 1 kb resolution in the GM12878 cell line. Subsequently, we measure Rambutan’s performance across six cell types. In this setting, the model achieves an area under the receiver operating characteristic curve between 0.7662 and 0.8246 and an area under the precision-recall curve between 0.3737 and 0.9008. We further demonstrate that the predicted contacts exhibit expected trends relative to histone modification ChlP-seq data, replication timing measurements, and annotations of functional elements such as promoters and enhancers. Finally, we predict Hi-C contacts for 53 human cell types and show that the predictions cluster by cellular function. [NOTE After our original submission we discovered an error in our calling of statistically significant contacts. Briefly, when calculating the prior probability of a contact, we used the number of contacts at a certain genomic distance in a chromosome but divided by the total number of bins in the full genome. When we corrected this mistake we noticed that the Rambutan model, as it curently stands, did not outperform simply using the GM12878 contact map that Rambutan was trained on as the predictor in other cell types. While we investigate these new results, we ask that readers treat this manuscript skeptically.]

biorxiv bioinformatics 0-100-users 2017

Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types, bioRxiv, 2017-01-26

ABSTRACTGenetics can provide a systematic approach to discovering the tissues and cell types relevant for a complex disease or trait. Identifying these tissues and cell types is critical for following up on non-coding allelic function, developing ex-vivo models, and identifying therapeutic targets. Here, we analyze gene expression data from several sources, including the GTEx and PsychENCODE consortia, together with genome-wide association study (GWAS) summary statistics for 48 diseases and traits with an average sample size of 169,331, to identify disease-relevant tissues and cell types. We develop and apply an approach that uses stratified LD score regression to test whether disease heritability is enriched in regions surrounding genes with the highest specific expression in a given tissue. We detect tissue-specific enrichments at FDR < 5% for 34 diseases and traits across a broad range of tissues that recapitulate known biology. In our analysis of traits with observed central nervous system enrichment, we detect an enrichment of neurons over other brain cell types for several brain-related traits, enrichment of inhibitory over excitatory neurons for bipolar disorder but excitatory over inhibitory neurons for schizophrenia and body mass index, and enrichments in the cortex for schizophrenia and in the striatum for migraine. In our analysis of traits with observed immunological enrichment, we identify enrichments of T cells for asthma and eczema, B cells for primary biliary cirrhosis, and myeloid cells for Alzheimer's disease, which we validated with independent chromatin data. Our results demonstrate that our polygenic approach is a powerful way to leverage gene expression data for interpreting GWAS signal.

biorxiv genetics 0-100-users 2017

Mass-spectrometry of single mammalian cells quantifies proteome heterogeneity during cell differentiation, bioRxiv, 2017-01-25

Cellular heterogeneity is important to biological processes, including cancer and development. However, proteome heterogeneity is largely unexplored because of the limitations of existing methods for quantifying protein levels in single cells. To alleviate these limitations, we developed Single Cell ProtEomics by Mass Spectrometry (SCoPE-MS), and validated its ability to identify distinct human cancer cell types based on their proteomes. We used SCoPE-MS to quantify over a thousand proteins in differentiating mouse embryonic stem (ES) cells. The single-cell proteomes enabled us to deconstruct cell populations and infer protein abundance relationships. Comparison between single-cell proteomes and transcriptomes indicated coordinated mRNA and protein covariation. Yet many genes exhibited functionally concerted and distinct regulatory patterns at the mRNA and the protein levels, suggesting that post-transcriptional regulatory mechanisms contribute to proteome remodeling during lineage specification, especially for developmental genes. SCoPE-MS is broadly applicable to measuring proteome configurations of single cells and linking them to functional phenotypes, such as cell type and differentiation potentials.

biorxiv genomics 200-500-users 2017